Certificate of Analysis and Data Sheet

Source:
Human Urine.

Catalog No.
PRO-321

Background:

Urinary Trypsin Inhibitor (UTI, Ulinastatin) is a kind of glucoprotein derived from human urine. As a proteinase inhibitor, Ulinastatin inhibits the activity of trypsin, chymotrypsin, lactate, lipase, hyaluronidase and other pancreatic enzymes. UTI is an effective for acute pancreatitis, chronic recurrent pancreatitis and hemorrhagic, traumatic and endotoxic shocks. Urinastatin is has strong inhibition effect to various protease, sugar and fat hydrolase. .

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

UTI was lyophilized after extensive dialysis against 50mM acetic acid.

Solubility:

It is recommended to reconstitute the lyophilized UTI in sterile 18M?cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Stability:

Lyophilized Ulinastatin although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution UTI should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.

Purity:

Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

Dimers and aggregates:

Less than 1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:

ProSpec TechnoGene's UTI measured biological activity of 1000 IU/mg.

Endotoxin:

Less than 0.1 ng/ug (IEU/ug) of Ulinastatin.

Protein content:

Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm.
2. Analysis by RP-HPLC, using a standard solution of UTI as a Reference Standard.

Usage:

Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Latest Publications:

1. Treating adult women with suspected UTI.
Am Fam Physician 2006 Jan 15;73(2):293-6
2. A study of sensitivity and resistance of pathogenic micro organisms causing UTI in Kathmandu valley.
Kathmandu Univ Med J (KUMJ) 2005 Apr-Jun;3(10):123-9
3. Amelioration of ischemia-reperfusion injury of transplanted small intestine by ulinastatin: effects on accumulation and adhesion of neutrophil.
Transplant Proc 2005 Dec;37(10):4464-6
4. Duration of therapy for women with uncomplicated UTI.
Am Fam Physician 2005 Dec 1;72(11):2219
5. [Protective effects of ulinastatin against multiple organic damage after severe burn injury: experimental and clinic studies]
Zhonghua Yi Xue Za Zhi 2005 Nov 2;85(41):2889-94
6. [Protective efficacy and probable mechanism of ulinastatin in patients with gastrointestinal cancer undergoing adjuvant chemotherapy]
Zhonghua Wei Chang Wai Ke Za Zhi 2005 Nov;8(6):487-9